ABL Bio, Sanofi sign $1bn deal for Parkinson’s candidate ABL301
ABL Bio has bagged a global collaboration and licensing deal worth up to $1.06 billion with Sanofi to develop and commercialize its drug candidate ABL301 for the treatment of Parkinson’s disease. According to the South Korean biotech firm, ABL301 is a pre-clinical stage bispecific antibody, which targets alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R). […]